Increased apoptosis of bone marrow cells and preserved proliferative capacity of selected progenitors predict for clinical response to anti- inflammatory therapy in myelodysplastic syndromes

Experimental Hematology

Volumn 28, Issue 8, 2000, Pages 941-949

  Novitzky, Nicolas ^a   Mohamed, Regana ^a   Finlayson, Jill ^a   Du Toit, Cecile ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Apoptosis; Bone marrow stroma; Cytokines; Dysplasia; Stem cells

Indexed keywords

CD34 ANTIGEN; CIPROFLOXACIN; DEXAMETHASONE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; MONOKINE; PENTOXIFYLLINE; RECOMBINANT INTERLEUKIN 3; STEM CELL FACTOR;

APOPTOSIS; ARTICLE; BLOOD CELL COUNT; BLOOD PRESSURE; BLOOD TRANSFUSION; BONE MARROW CELL; BONE MARROW CULTURE; CELL PROLIFERATION; CLINICAL ARTICLE; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG WITHDRAWAL; FLUID RETENTION; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; MYELODYSPLASTIC SYNDROME; NAUSEA; NICK END LABELING; PRIORITY JOURNAL; STEM CELL; VOMITING;

ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD34; APOPTOSIS; BLOOD TRANSFUSION; BONE MARROW CELLS; CELL DIVISION; CIPROFLOXACIN; DEXAMETHASONE; GLUCOCORTICOIDS; HUMANS; IN SITU NICK-END LABELING; LEUKOCYTE COUNT; MYELODYSPLASTIC SYNDROMES; PENTOXIFYLLINE; STEM CELLS; STROMAL CELLS;

EID: 0033831785     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(00)00489-6     Document Type: Article

References (35)

1. Bennett J.M., Catovsky D., Daniel M.T.et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 51:1982;189.
2. Greenberg P., Cox C., LeBeau M.M.et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 89:1997;2079.
3. Merchav S., Nielsen O.J., Rosenbaum H.et al. In vitro studies of erythropoietin dependent regulation of erythropoiesis in myelodysplastic syndromes. Leukaemia. 4:1990;771.
4. Merchav S., Wagemaker G., Souza L.M., Tatarsky I. Impaired response of myelodysplastic marrow progenitors to stimulation with recombinant haemopoietic growth factors. Leukemia. 5:1991;340.
5. Aoki I., Higashi K., Homori M., Chikazawa H., Ishikawa K. Responsiveness of bone marrow erythropoietic stem cells (CFU-E and BFU-E) to recombinant human erythropoietin in vitro, in aplastic anemia and myelodysplastic syndrome. Am J Hematol. 35:1990;6.
6. Rose E.H., Abels R.I., Nelson R.A., McCullough D.M., Lesin L. The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). Br J Haematol. 89:1995;831.
7. Shetty V., Mundle S., Alvi S.et al. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk Res. 20:1996;881.
8. Mundle S.D., Venugopal P., Cartlidge J.D.et al. Indication of an involvement of interleukin-1 beta converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes. Blood. 88:1996;2640.
9. Raza A., Mundle S., Shetty V.et al. Novel insights into the biology of myelodysplastic syndromes. excessive apoptosis and the role of cytokines Int J Hemat. 63:1996;265.
10. Raza A., Alvi S., Broady-Robinson L.et al. Cell cycle kinetic studies in 68 patients with myelodysplastic syndromes, following intravenous iodo- and/or bromodeoxyuridine. Exp Hematol. 25:1997;530.
11. Jacobs A., Janowska-Wieczorek A., Caro J., Bowen D.T., Lewis T. Circulating erythropoietin in patients with myelodysplastic syndromes. Br J Haematol. 73:1989;36.
12. Dexter T.M., Allen T.D., Lajtha L.G. Conditions controlling the proliferation of haemopoietic stem cells in vitro. J Cell Physiol. 91:1977;335.
13. Gartner S., Kaplan H.S. Long term culture of human bone marrow. In. Modern trends in human leukemia; Hematology and Blood Transfusion 26, IV:1981;276-288 Springer Verlag, Berlin.
14. Duhrsen U., Hossfeld D.K. Stromal abnormalities in neoplastic bone marrow diseases. Ann Hematol. 73:1996;53.
15. Asano H., Hotta T., Ichihara M., Murate T., Kobayashi M., Saito H. Growth analysis of marrow CD34-positive hematopoietic progenitor cells in patients with myelodysplastic syndromes. Leukemia. 8:1994;833.
16. Arcenas A.G., Vadhan-Raj S. Hematopoietic growth factor therapy of myelodysplastic syndromes. Leuk Lymphoma. 11(suppl.2):1993;65.
17. Gorczyca W., Gong J., Darzynkiewicz Z. Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assay. Cancer Res. 53:1993;1945.
18. Gordon M.Y., Goldman J.M., Gordon-Smith E.C. 4-Hydroperoxycyclo-phosphamide inhibits proliferation of human granulocyte-macrophage colony-forming cells (GM-CFC) but spares more primitive progenitor cells. Leuk Res. 9:1985;1017.
19. Novitzky N., Mohamed R. Alterations in both the haematopoietic microenvironment and the progenitor cell population follow the recovery from myeloablative therapy and bone marrow transplantation. Exp Hematol. 23:1995;161.
20. Novitzky N., Kruger W., Mohamed R. Cryopreservation of the bone marrow from patients with acute myeloid leukaemia leads to functional abnormalities. Eur J Hematol. 62:1999;83.
21. Novitzky N., Mohamed R. Alterations in the progenitor cell population follow recovery from myeloablative therapy and bone marrow transplantation. Exp Hematol. 25:1997;471.
22. Novitzky N., Pillay G.S., Hallet J.et al. Qualitative abnormalities characterise haematopoiesis that restores marrow function following therapy with antilymphocyte globulin and high dose methyl prednisolone in aplastic anaemia. Int J Pediatr Hematol Oncol. 3:1996;423.
23. Gupta P., Niehans G.A., LeRoy S.C.et al. Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival. Leukemia. 13:1999;44.
24. Goliaei B., Soheili Z., Behboodi A., Samiei S. Hematopoiesis in the presence of macrophages in long-term bone marrow cultures. Exp Hematol. 23:1995;1115.
25. Vadhan-Raj S., Keating M., LeMaistre A.et al. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med. 317:1987;1545.
26. De Witte T. New treatment approaches for myelodysplastic syndrome and secondary leukaemias. Ann Oncol. 5:1994;401.
27. Nemunaitis J., Rosenfeld C., Getty L., Boegel F., Meye W., Jennings L.W., Zeigler Z., Shadduck R. Pentoxifylline and ciprofloxacin in patients with myelodysplastic syndrome. A phase II trial. Am J Clin Oncol. 18:1995;189.
28. Raza S., Shetty V., Dar S., Qawi H., Raza A. Tumor necrosis factor-alpha levels decrease with anticytokine therapy in patients with myelodysplastic syndromes. J Interferon Cytokine Res. 18:1998;871.
29. Tichelli A., Gratwohl A., Wuersch A., Nissen C., Speck B. Antilymphocyte globulin for myelodysplastic syndrome. Br J Haematol. 68:1988;139.
30. Biesma D.H., van den Tweel J.G., Verdonck L.F. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer. 79:1997;1548.
31. Enright H., Jacob H.S., Vercellotti G., Howe R., Belzer M., Miller W. Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes. response to immunosuppressive therapy Br J Haematol. 91:1995;403.
32. Gersuk G.M., Beckham C., Loken M.R.et al. A role for tumor necrosis alspha, Fas and Fas ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol. 103:1998;176.
33. Dar S., Mundle S., Andric T.et al. Biological characteristics of myelodysplastic syndrome patients who demonstrated high versus no intramedullary apoptosis. Eur J Haematol. 62:1999;90.
34. Bouscary D., De Vos J., Guesnu M.et al. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia. 11:1997;839.
35. Hellstrom-Lindberg E., Kanter-Lewensohn L., Ost A. Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leuk Res. 21:1997;415.